JP2011529044A - イノシトール及びトレハロース誘導体、及びこれを含む退行性脳神経系疾患治療用医薬組成物 - Google Patents
イノシトール及びトレハロース誘導体、及びこれを含む退行性脳神経系疾患治療用医薬組成物 Download PDFInfo
- Publication number
- JP2011529044A JP2011529044A JP2011519969A JP2011519969A JP2011529044A JP 2011529044 A JP2011529044 A JP 2011529044A JP 2011519969 A JP2011519969 A JP 2011519969A JP 2011519969 A JP2011519969 A JP 2011519969A JP 2011529044 A JP2011529044 A JP 2011529044A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mmol
- inositol
- mixture
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C1C=C)C11C2=CCC*2CC1C* Chemical compound CC(C1C=C)C11C2=CCC*2CC1C* 0.000 description 6
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/04—Disaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/02—Monosaccharides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【選択図】 図1
Description
R1は、水素、R、アルキルまたは−COR’であり、ここでR’は水素、アルキル、アミノアルキル、アリールアルキル、シクロアルキルまたはヘテロアルキルである。
R1及びR2は、それぞれ独立的に水素、アルキルまたは−COR’であるが、ここでR’は水素、アルキル、アミノアルキル、アリールアルキル、シクロアルキルまたはヘテロアルキルである。
R1は、水素、R、アルキルまたは−COR’であるが、ここでR’は水素、アルキル、アミノアルキル、アリールアルキル、シクロアルキル、ヘテロアルキルまたは蛍光物質である。
R1は、水素、R、アルキル、アリールアルキル、シクロアルキルまたはヘテロアルキルであり;
R2は、水素、R、またはトリチルである。
R1は、水素、R、アルキル、または−COR’であり、ここでR’は水素、アルキル、アミノアルキル、アリールアルキル、シクロアルキル、またはヘテロアルキルである。
R1及びR2はそれぞれ独立的に水素、アルキル、または−COR’であるが、ここでR’は水素、アルキル、アミノアルキル、アリールアルキル、シクロアルキル、またはヘテロアルキルである。
R1は、水素、R、アルキル、または−COR’であるが、ここでR’は水素、アルキル、アミノアルキル、アリールアルキル、シクロアルキル、ヘテロアルキル、または蛍光プローブである。
R1は、水素、R、アルキル、アリールアルキル、シクロアルキル、またはヘテロアルキルであり;
R2は、水素、R、またはトリチルである。
<2−1>カルボベンゾキシ(Cbz)基によって保護されたリンカーの導入
1H NMR(in MeOD,δ)3.37(app.t,6H,J=3.8 Hz),3.57(dd,2H,J=9.7 and 3.8 Hz),3.79(app.t,2H,J=9.3 Hz),4.02−4.09(m,2H),5.36(d,2H,J=3.8 Hz,anomeric protons),7.14−7.25(m,18H,trityl protons),7.41−7.52(m,12H,trityl protons)。
MS(MALDI−TOF): m/z 3233.606(M+)。
MS(MALDI−TOF): m/z 1633.085(M+)。
実施例1(94.5mg/kg)、実施例2(59.5mg/kg)、実施例3(84.5mg/kg)、実施例5(90.9mg/kg)及び実施例8(83.1mg/kg)において製造した化合物をそれぞれ蒸留水に溶かして、生後8週齢のC57BL/6マウス(Hyochang Science Inc.韓国)に腹腔内注射した。20分後、注射したマウスを溶液(4%パラホルムアルデヒドPBS溶液(pH7.4))で処理して、各マウスから脳を摘出して0.5MスクロースPBS溶液に一日中放置した。
Claims (9)
- 前記式(1)の化合物が、scyllo−、myo−、epi−、chiro−、allo−、muco−、neo−、またはcis−イノシトール異性質体に該当する立体化学構造を有することを特徴とする請求項1に記載のイノシトール誘導体またはその塩。
- 前記式(2)の化合物が、scyllo−、myo−、epi−、またはchiro−イノシトール異性質体に該当する骨格構造を有することを特徴とする請求項3に記載のイノシトール誘導体またはその塩。
- 前記式(4)の化合物が、D−グルコース、D−マンノース、D−アロース、またはD−ガラクトースの骨格構造を有することを特徴とする請求項6に記載の単糖類誘導体またはその塩。
- 請求項1〜7のいずれか一項に記載の化合物を有効成分として含む、退行性脳神経系疾患の治療用医薬組成物。
- 前記退行性脳神経系疾患が、アルツハイマー病、ハンチントン病、または他の関連疾患を含むことを特徴とする請求項8に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080071383A KR101021078B1 (ko) | 2008-07-22 | 2008-07-22 | 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물 |
KR10-2008-0071383 | 2008-07-22 | ||
PCT/KR2009/001470 WO2010011012A1 (en) | 2008-07-22 | 2009-03-23 | Inositol and trehalose derivatives and pharmaceutical compositions for treating neurodegenerative diseases comprising the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011529044A true JP2011529044A (ja) | 2011-12-01 |
JP5410522B2 JP5410522B2 (ja) | 2014-02-05 |
Family
ID=41570452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011519969A Expired - Fee Related JP5410522B2 (ja) | 2008-07-22 | 2009-03-23 | イノシトール及びトレハロース誘導体、及びこれを含む退行性脳神経系疾患治療用医薬組成物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20110224423A1 (ja) |
EP (2) | EP2321265A4 (ja) |
JP (1) | JP5410522B2 (ja) |
KR (1) | KR101021078B1 (ja) |
DK (1) | DK2987798T3 (ja) |
WO (1) | WO2010011012A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013097147A1 (zh) | 2011-12-29 | 2013-07-04 | 华为技术有限公司 | 云计算系统和管理云计算系统中存储资源的方法 |
CN104470817A (zh) * | 2012-07-20 | 2015-03-25 | 国际密封系统公司 | 轻重量闭合件和容器包装 |
US9084720B2 (en) | 2013-05-07 | 2015-07-21 | BioBlast Pharma Ltd. | Compositions and methods for treating oculopharyngeal muscular dystrophy |
EA201501054A1 (ru) * | 2013-05-07 | 2016-04-29 | Био Бласт Фарма Лтд. | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы |
KR20160001419A (ko) | 2014-06-27 | 2016-01-06 | 포항공과대학교 산학협력단 | 양이온성 분자 수송체 및 음이온성 생리활성 물질을 포함하는 피부 투과용 조성물 |
KR20160095849A (ko) | 2015-02-04 | 2016-08-12 | 한남대학교 산학협력단 | 퇴행성 신경계 질환의 치료제 후보 물질 스크리닝 방법 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007523889A (ja) * | 2004-03-05 | 2007-08-23 | ポステック・ファウンデーション | イノシトール系分子輸送体及びその製造方法 |
JP2008063316A (ja) * | 2006-09-07 | 2008-03-21 | Postech Academy-Industry Foundation | アルジトールまたはイノシトール誘導体を骨格とする分子輸送体 |
JP2008539226A (ja) * | 2005-04-28 | 2008-11-13 | ポステック・ファウンデーション | 糖及びその類似体を骨格とする分子輸送体並びにその製造方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
US20070111970A1 (en) * | 2005-10-13 | 2007-05-17 | Antonio Cruz | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence |
-
2008
- 2008-07-22 KR KR1020080071383A patent/KR101021078B1/ko active IP Right Grant
-
2009
- 2009-03-23 DK DK15186646.4T patent/DK2987798T3/da active
- 2009-03-23 EP EP09800493A patent/EP2321265A4/en not_active Withdrawn
- 2009-03-23 JP JP2011519969A patent/JP5410522B2/ja not_active Expired - Fee Related
- 2009-03-23 EP EP15186646.4A patent/EP2987798B1/en not_active Not-in-force
- 2009-03-23 US US13/003,414 patent/US20110224423A1/en not_active Abandoned
- 2009-03-23 WO PCT/KR2009/001470 patent/WO2010011012A1/en active Application Filing
-
2014
- 2014-10-08 US US14/509,175 patent/US9371350B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007523889A (ja) * | 2004-03-05 | 2007-08-23 | ポステック・ファウンデーション | イノシトール系分子輸送体及びその製造方法 |
JP2008539226A (ja) * | 2005-04-28 | 2008-11-13 | ポステック・ファウンデーション | 糖及びその類似体を骨格とする分子輸送体並びにその製造方法 |
JP2008063316A (ja) * | 2006-09-07 | 2008-03-21 | Postech Academy-Industry Foundation | アルジトールまたはイノシトール誘導体を骨格とする分子輸送体 |
Also Published As
Publication number | Publication date |
---|---|
EP2321265A4 (en) | 2012-04-04 |
WO2010011012A1 (en) | 2010-01-28 |
EP2987798B1 (en) | 2017-08-09 |
JP5410522B2 (ja) | 2014-02-05 |
US20110224423A1 (en) | 2011-09-15 |
KR20100010418A (ko) | 2010-02-01 |
DK2987798T3 (da) | 2017-11-13 |
KR101021078B1 (ko) | 2011-03-14 |
US20150025035A1 (en) | 2015-01-22 |
US9371350B2 (en) | 2016-06-21 |
EP2321265A1 (en) | 2011-05-18 |
EP2987798A1 (en) | 2016-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9371350B2 (en) | Trehalose derivatives and pharmaceutical compositions for treating neurodegenerative diseases | |
US10800804B2 (en) | Hybrid galactoside inhibitor of galectins | |
DE69229557T2 (de) | Neue sphingoglycolipide und verwendung davon | |
JP3004297B2 (ja) | リゾスフィンゴ脂質誘導体 | |
US8445272B2 (en) | Method of stimulating NKT with 6″-amino-6″-deoxygalactosylceramides | |
CA2814247C (en) | Polymorphic and amorphous salt forms of squalamine dilactate | |
WO2020078807A1 (en) | Prodrug of galactoside inhibitors of galectins | |
AU2014318014C1 (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
CA2519568C (en) | 6"-amino-6"-deoxygalactosylceramides | |
US8163713B2 (en) | Trehalose compound and pharmaceutical comprising the compound | |
WO2011096536A1 (ja) | 新規合成糖脂質およびその用途 | |
CN106660992B (zh) | 二甲基吡啶胺衍生物及其医药用途 | |
AU2013264896A1 (en) | Compositions and methods for the treatment of multiple sclerosis | |
KR101969129B1 (ko) | 알파-갈락토실세라마이드 유사체, 이의 제조방법 및 이를 포함하는 면역조절 이상으로 인한 질환의 치료 또는 예방용 약학적 조성물 | |
DE68914418T2 (de) | Lysoganglioside-Derivate. | |
WO2017035733A1 (zh) | 美金刚与牛蒡子苷元的缀合物及其组合物和用途 | |
EP4011897A1 (en) | Salt and crystal form of steroid derivative regulator | |
TW201442739A (zh) | 過敏疾病治療藥 | |
DE69033027T2 (de) | Di-lysogangliosidderivate | |
EP2289904A1 (en) | Inhibitors of microbial infections | |
CN110857285B (zh) | 取代吡唑类化合物、其制备方法、药物组合物及用途 | |
KR20210013081A (ko) | 나프록센 및 프레가발린의 1-(아실옥시)-알킬 카르바메이트 약물 복합체의 결정형 | |
US11834463B2 (en) | High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders | |
WO2014068459A2 (en) | Compositions and methods for the treatment of pain and neurological diseases | |
CA3044908A1 (en) | Silylated derivatives of reservatrol and the use thereof in neurodegenerative, neurological, or inflammatory diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130509 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130514 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130814 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130821 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130906 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131008 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131106 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5410522 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |